We are live on ! Find out more
SCM

Sio Capital Management Portfolio holdings

AUM $697M
1-Year Est. Return 79.73%
This Fund
S&P 500
This Quarter Est. Return
-1.39%
1 Year Est. Return
+79.73%
3 Year Est. Return
+576.62%
5 Year Est. Return
+422.76%
10 Year Est. Return
+2,506.65%
AUM
$402M
AUM Growth
-$90.4M
Cap. Flow
-$75.3M
Cap. Flow %
-18.72%
Top 10 Hldgs %
43.57%
Holding
105
New
16
Increased
19
Reduced
23
Closed
32

Top Buys

Rank Stock Value
1
AVAH icon
Aveanna Healthcare
AVAH
+$14.3M
2
AMGN icon
Amgen
AMGN
+$8.61M
3
ITGR icon
Integer Holdings
ITGR
+$6.16M
4
HQY icon
HealthEquity
HQY
+$4.95M
5
SYRS
Syros Pharmaceuticals, Inc. Common Stock
SYRS
+$4.74M

Top Sells

Rank Stock Value
1
CAH icon
Cardinal Health
CAH
+$14.1M
2
CRIS icon
Curis
CRIS
+$11.5M
3
MRK icon
Merck
MRK
+$9.64M
4
ICLR icon
Icon
ICLR
+$9.33M
5
GSK icon
GSK
GSK
+$9.19M

Sector Composition

Rank Sector Weight
1 Healthcare 79.43%
2 Consumer Staples 2.03%
3 Technology 0.88%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ASLN
26
DELISTED
ASLAN Pharmaceuticals Limited American Depositary Shares
ASLN
$4.91M 1.22%
37,213
+1,000
+3% +$125K
VRTX icon
27
Vertex Pharmaceuticals
VRTX
$121B
$4.82M 1.2%
23,900
+2,833
+13% +$593K
KURA icon
28
Kura Oncology
KURA
$800M
$4.63M 1.15%
222,263
+8,792
+4% +$218K
CCRN
29
DELISTED
Cross Country Healthcare
CCRN
$4.62M 1.15%
279,850
-153,394
-35% -$2.34M
RDUS
30
DELISTED
Radius Health, Inc.
RDUS
$4.39M 1.09%
240,957
+10,000
+4% +$199K
CHAQ.U
31
DELISTED
Chardan Healthcare Acquisition 2 Corp. Units, each consisting of one share of Common Stock, and one
CHAQ.U
$4.37M 1.09%
+400,000
New +$4.23M
SYRS
32
DELISTED
Syros Pharmaceuticals, Inc. Common Stock
SYRS
$4.36M 1.08%
+80,000
New +$4.74M
NARI
33
DELISTED
Inari Medical, Inc. Common Stock
NARI
$4.32M 1.07%
+46,332
New +$4.49M
EPIX
34
DELISTED
ESSA Pharma
EPIX
$4.23M 1.05%
148,127
-164,584
-53% -$4.78M
NBSE
35
DELISTED
NeuBase Therapeutics, Inc. Common Stock
NBSE
$4.16M 1.03%
43,435
+23,750
+121% +$2.62M
ARDX icon
36
Ardelyx
ARDX
$1.22B
$3.99M 0.99%
525,996
-194,625
-27% -$1.44M
AUTL
37
Autolus Therapeutics
AUTL
$397M
$3.93M 0.98%
+591,870
New +$3.67M
VKTX icon
38
Viking Therapeutics
VKTX
$3.7B
$3.71M 0.92%
619,780
+50,000
+9% +$297K
MBRX icon
39
Moleculin Biotech
MBRX
$2.83M
$3.69M 0.92%
2,680
+112
+4% +$153K
DTIL icon
40
Precision BioSciences
DTIL
$180M
$3.67M 0.91%
9,781
-1,198
-11% -$360K
RIGL icon
41
Rigel Pharmaceuticals
RIGL
$681M
$3.6M 0.9%
+82,972
New +$3.13M
EFOR
42
Everforth Inc
EFOR
$1.17B
$3.56M 0.88%
36,692
+2,115
+6% +$216K
EUCRU
43
DELISTED
Eucrates Biomedical Acquisition Corp. Unit
EUCRU
$3.06M 0.76%
300,000
– –
MGNX icon
44
MacroGenics
MGNX
$235M
$3.02M 0.75%
112,587
-17,413
-13% -$510K
SYRE icon
45
Spyre Therapeutics
SYRE
$8.54B
$2.8M 0.7%
16,106
– –
GYRE icon
46
Gyre Therapeutics
GYRE
$641M
$2.7M 0.67%
83,186
– –
PRQR icon
47
ProQR Therapeutics
PRQR
$243M
$2.56M 0.64%
380,045
-12,776
-3% -$82.4K
OBIO icon
48
Orchestra BioMed
OBIO
$238M
$2.55M 0.63%
250,000
– –
AMN icon
49
AMN Healthcare
AMN
$1.3B
$2.52M 0.63%
26,001
-97,897
-79% -$8.5M
BGMS
50
Bio Green Med Solution Inc
BGMS
$4.91M
$2.47M 0.61%
+116
New +$2.88M
1
2
3 4 5

Similar funds

GUB
Golden Unicorn BVI Road Town $697M AUM 55.92% 1-Year Est. Return
KLI
Kelman-Lazarov Inc Memphis, Tennessee $698M AUM 14.07% 1-Year Est. Return
JA
JLB & Associates Plymouth, Michigan $696M AUM 17.86% 1-Year Est. Return
WIC
Wilkins Investment Counsel Boston, Massachusetts $698M AUM 17.36% 1-Year Est. Return
AAM
Auxier Asset Management Aurora, Oregon $696M AUM 18.07% 1-Year Est. Return
TCM
Tensile Capital Management Larkspur, California $698M AUM 2.4% 1-Year Est. Return
CA
Calton & Associates Tampa, Florida $696M AUM 18.3% 1-Year Est. Return
SAM
Silverback Asset Management Chapel Hill, North Carolina $699M AUM 72.42% 1-Year Est. Return

Sio Capital Management's Q2 2021 Portfolio in Review

As of Q2 2021, Sio Capital Management held 105 positions worth $402M, down 18% from $493M the previous quarter. Its ten largest holdings account for 44% of the portfolio.

Sio Capital Management withdrew a net $75.3M in Q2 2021, closing 32 positions and reducing 23 holdings. Its most notable exit was Merck, an estimated $9.64M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 79% of assets, down from 87% a quarter earlier, followed by Consumer Staples and Technology.

Against the trend, Sio Capital Management opened a new position in Aveanna Healthcare worth $14.9M.

  • Sio Capital Management's largest Q2 2021 buy was Aveanna Healthcare: 1,201,607 shares worth $14.9M.
  • Sio Capital Management added most to NeuBase Therapeutics, Inc. Common Stock in Q2 2021, an estimated $2.62M increase.
  • Sio Capital Management's biggest Q2 2021 reduction was Cardinal Health, cutting an estimated $14.1M.
  • Sio Capital Management fully exited Merck in Q2 2021, selling an estimated $9.64M.
  • Sio Capital Management's ten largest holdings make up 44% of its $402M portfolio in Q2 2021.
  • Sio Capital Management opened 16 new positions and closed 32 in Q2 2021.
  • Sio Capital Management's portfolio value fell 18% quarter-over-quarter to $402M.

Based on Sio Capital Management's 13F filing for Q2 2021, filed 16 Aug 2021.